The pace of change in the life sciences industry is startling and is putting traditional IP management strategies under extreme pressure. It may be time for IP leaders to start looking to the tech industry experience for lessons in how to respond.
Insurance products relating to patents and other rights are not new, but they have never really taken off. Now, though, the industry's heavy hitters are moving in and things could be about to change.
“The patent market has fully stabilised and prices are rational,” said no one ever. During 2018 total dollars transacted in brokered deals increased while prices of single-asset deals have dropped significantly.
Boards and directors typically prioritise non-IP issues on the corporate agenda; however, legal requirements and market activities suggest that this might be a serious misstep.
Interconnectivity is the key to maximising IoT's potential - and that means finding effective ways to ensure access to the IP required to make it happen.
The heads of intellectual property at Swedish automaker Volvo Car Corporation and Swiss wireless communications supplier u-blox AG believe that the EPO must play a central role in deciding on mobile technology SEPs.
Life sciences companies in the United States are under increasing pressure. Campaigners for changes to the patent system are working to prevent what they see as abusive practices – and it looks as if they are winning the argument.
Just months after a private equity takeover, RPX has appointed an industry veteran as its new CEO. But with a declining financial performance and questions remaining over the future of its discovery business, Dan McCurdy (left) will need all of his experience to turn around one of the patent market’s most iconic businesses.
How to ensure that the use of open source packages does not run contrary to corporate IP policies.